Increased survival time or better quality of life? Trade-off between benefits and adverse events in the systemic treatment of cancer

Introduction Primary objective of the study was to assess the relative weighting between benefit in survival time (SV), benefit in quality of life (QoL) and willingness to experience adverse events (AEs), in patient preferences for chemotherapy treatment.